Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/2/2025

Management of Dizziness and Vertigo in Palliative Care

Primary Treatment Approach

  • The American Academy of Otolaryngology-Head and Neck Surgery recommends avoiding routine use of vestibular suppressants, such as meclizine, antihistamines, and benzodiazepines, in palliative and hospice patients with dizziness and vertigo, as they provide no definitive benefit and may worsen outcomes 1, 2
  • Vestibular suppressants, including antihistamines and benzodiazepines, are not recommended for treating vertigo in any population, including palliative patients, due to lack of evidence of effectiveness and potential to mask symptoms without addressing underlying causes 1, 2
  • The American Academy of Otolaryngology-Head and Neck Surgery suggests that vestibular suppressants may be used only for short-term management of severe symptoms in severely symptomatic patients who refuse other options 1, 2

Identify and Treat Underlying Causes

  • The European Society for Medical Oncology recommends reviewing and discontinuing medications that may cause or worsen vertigo, including chemotherapeutic agents, immunotherapies, opioids, NSAIDs, anticonvulsants, and antidepressants 5
  • Evaluation and correction of hyponatremia from SIADH, common in small cell lung cancer, platinum-based chemotherapy, vinca alkaloids, and opioids, is recommended by the European Society for Medical Oncology 5

Non-Pharmacological Interventions

  • Vestibular rehabilitation therapy is strongly advised for most patients with vestibular disorders, as it promotes central compensation and long-term recovery, according to the American Academy of Otolaryngology-Head and Neck Surgery 1, 2

Special Considerations for Palliative Sedation

  • The European Society for Medical Oncology recommends palliative sedation with midazolam, levomepromazine, chlorpromazine, phenobarbital, or propofol for refractory vertigo in imminently dying patients 4

Common Pitfalls to Avoid

  • The American Academy of Otolaryngology-Head and Neck Surgery advises against continuing vestibular suppressants long-term, as this delays recovery by interfering with central compensation 1, 2, 6
  • The American Academy of Otolaryngology-Head and Neck Surgery recommends against prescribing meclizine as primary treatment for BPPV or other vestibular disorders in any patient population 1, 2, 6

Reassessment

  • The American Academy of Otolaryngology-Head and Neck Surgery recommends reassessing patients within 1 month to confirm symptom resolution or identify treatment failures requiring alternative approaches 1, 7

REFERENCES

1

clinical practice guideline: benign paroxysmal positional vertigo. [LINK]

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2008

2

clinical practice guideline: benign paroxysmal positional vertigo. [LINK]

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2008

5

clinical practice guideline: benign paroxysmal positional vertigo (update). [LINK]

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2017

6

clinical practice guideline: benign paroxysmal positional vertigo. [LINK]

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2008